AbCellera Biologics (NASDAQ:ABCL) Posts Quarterly Earnings Results, Beats Estimates By $0.15 EPS

AbCellera Biologics (NASDAQ:ABCL) released its quarterly earnings results on Tuesday. The company reported ($0.03) earnings per share for the quarter, beating the consensus estimate of ($0.18) by $0.15, Zacks reports. The firm had revenue of $44.85 million for the quarter, compared to analysts’ expectations of $6.31 million. AbCellera Biologics had a negative return on equity of 14.93% and a negative net margin of 198.37%.

Here are the key takeaways from AbCellera Biologics’ conference call:

• AbCellera says its transition to a vertically integrated clinical?stage biotech is complete, having finished platform investments and its clinical manufacturing facility, and it reports approximately $700 million in available liquidity to fund pipeline execution.
• Lead program ABCL635 is in a randomized, double?blind Phase 2 with a pivotal readout expected in Q3 2026 that management views as highly de?risking and capable of supporting blockbuster potential if it matches or exceeds competitors on efficacy, safety, and once?monthly dosing — though uncertainty about hot?flash biology remains.
• ABCL575 (OX40 ligand) is in Phase 1 and management maintains conviction in the class and its combination potential despite recent external safety signals (Kaposi’s sarcoma), with a Phase 1 readout targeted by year?end 2026.
• Two additional internal candidates, ABCL688 (autoimmunity) and ABCL386 (oncology), are in IND?enabling activities with plans to file INDs/CTAs and start Phase 1/2 studies in 2027, and the company expects to nominate another development candidate in H1 2026.
• 2025 revenue rose to $75 million (including a $36 million patent?settlement benefit), R&D spend increased to $187 million and net loss was $146 million, but management says cash, marketable securities and committed government funding provide a multi?year runway to advance the internal pipeline.

AbCellera Biologics Trading Up 1.7%

NASDAQ:ABCL opened at $3.24 on Thursday. AbCellera Biologics has a 12 month low of $1.89 and a 12 month high of $6.51. The firm has a fifty day simple moving average of $3.64 and a 200-day simple moving average of $4.22. The company has a market capitalization of $970.73 million, a P/E ratio of -6.58 and a beta of 0.81.

Hedge Funds Weigh In On AbCellera Biologics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Engineers Gate Manager LP purchased a new stake in AbCellera Biologics in the 4th quarter worth approximately $38,000. Magnetar Financial LLC acquired a new position in shares of AbCellera Biologics in the 4th quarter valued at $49,000. Lantern Wealth Advisors LLC purchased a new stake in AbCellera Biologics during the second quarter worth $51,000. Oxford Asset Management LLP acquired a new stake in AbCellera Biologics during the fourth quarter valued at $51,000. Finally, Invesco Ltd. raised its position in shares of AbCellera Biologics by 114.6% in the first quarter. Invesco Ltd. now owns 24,146 shares of the company’s stock worth $54,000 after acquiring an additional 12,893 shares during the period. Hedge funds and other institutional investors own 61.42% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on ABCL shares. Leerink Partners cut shares of AbCellera Biologics from a “strong-buy” rating to a “hold” rating in a research report on Friday, November 7th. Wall Street Zen raised shares of AbCellera Biologics from a “sell” rating to a “hold” rating in a research note on Saturday, February 14th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of AbCellera Biologics in a research report on Wednesday, January 21st. Three investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $7.75.

About AbCellera Biologics

AbCellera Biologics Inc (NASDAQ: ABCL) is a biotechnology company specializing in the discovery and development of therapeutic antibodies. The company’s technology platform integrates single-cell screening, microfluidics, high-throughput sequencing and artificial intelligence to rapidly identify and optimize antibody candidates against a wide range of disease targets. By combining experimental data with machine learning, AbCellera accelerates early-stage drug discovery and improves the efficiency of lead candidate selection.

AbCellera primarily operates through partnerships with pharmaceutical and biotechnology firms, offering its antibody discovery services on a fee-for-service and milestone-driven basis.